Combination of PDL-1 and PARP inhibition in an unselected population with metastatic castrate-resistant prostate cancer (mCRPC).Fatima Karzai, Jung‐Min Lee, Anna Couvillon et al.|Journal of Clinical Oncology|2017Cited by 22
A phase II study of the anti-programmed death ligand-1 antibody durvalumab (D; MEDI4736) in combination with PARP inhibitor, olaparib (O), in metastatic castration-resistant prostate cancer (mCRPC).Fatima Karzai, Jung‐Min Lee, Ravi A. Madan et al.|Journal of Clinical Oncology|2017Cited by 20